Inventor · disambiguated record
Herbert K. Lyerly
Also filed as: LYERLY HERBERT · LYERLY HERBERT K · LYERLY HERBERT KIM
12 granted patents·11 pending applications·36 citations·filing 2009–2023
87Inventor score
Top patents by PatentIndex Score
23 records- 0193US10562864B2Chemical modulators of immune checkpoints and therapeutic useUNIV DUKE·Filed 2018·Granted Feb 18, 2020·11 cites·4 claims
- 0293US10189797B2Chemical modulators of immune checkpoints and therapeutic useUNIV DUKE·Filed 2016·Granted Jan 29, 2019·11 cites·19 claims
- 0384US10487143B2Vaccines against HER3 antigens and methods of using the sameUNIV DUKE·Filed 2017·Granted Nov 26, 2019·3 cites·19 claims
- 0482US9956276B2Vaccines against antigens involved in therapy resistance and methods of using sameUNIV DUKE·Filed 2013·Granted May 1, 2018·8 cites·16 claims
- 0581US10842857B2Vaccines against an oncogenic isoform of HER2 (ErbB2) and methods of using the sameUNIV DUKE·Filed 2018·Granted Nov 24, 2020·1 cites·16 claims
- 0678US11235043B2Vaccines against antigens involved in therapy resistance and methods of using sameUNIV DUKE·Filed 2018·Granted Feb 1, 2022·1 cites·17 claims
- 0771US12083172B2Vaccines against an oncogenic isoform of HER2 (ErbB2) and methods of using the sameUNIV DUKE·Filed 2020·Granted Sep 10, 2024·0 cites·12 claims
- 0869US10905665B2Chemical modulators of signaling pathways and therapeutic useUNIV DUKE·Filed 2016·Granted Feb 2, 2021·1 cites·2 claims
- 0968US10842855B2Vaccines against an oncogenic isoform of ESR1 and methods of using the sameUNIV DUKE·Filed 2018·Granted Nov 24, 2020·0 cites·16 claims
- 1064US2024165228A1Targeted inhibition of dkk3 to sensitize tumors to immunotherapyUNIV DUKE·Filed 2023·Application pending·0 cites
- 1164US2021069309A1Vaccines against an oncogenic isoform of esr1 and methods of using the sameUNIV DUKE·Filed 2020·Application pending·0 cites
- 1259US2025205467A1Systems and methods for the treatment of cancer using ultrasoundUNIV DUKE·Filed 2023·Application pending·0 cites
- 1355US11224665B2Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the sameUNIV DUKE·Filed 2017·Granted Jan 18, 2022·0 cites·13 claims
- 1451US2017196953A1VACCINES AGAINST AN ONCOGENIC ISOFORM OF HER2 (ErbB2) AND METHODS OF USING THE SAMEUNIV DUKE·Filed 2015·Application pending·0 cites
- 1551US2021330773A1Vaccines against antigens involved in therapy resistance and methods of using sameUNIV DUKE·Filed 2021·Application pending·0 cites
- 1651US2011236907A1Radiolabled cyclopamine assay for the smoothened receptorCHEN WEI·Filed 2009·Application pending·0 cites
- 1750US11987579B2Niclosamide analogues and therapeutic use thereofUNIV DUKE·Filed 2019·Granted May 21, 2024·0 cites·20 claims
- 1849US2022049015A1Compositions and methods for the treatment and/or prevention of her2+ cancersUNIV DUKE·Filed 2019·Application pending·0 cites
- 1946US11253580B2Cancer vaccines and methods of deliveryUNIV DUKE·Filed 2017·Granted Feb 22, 2022·0 cites·7 claims
- 2045US2017196952A1Vaccines against an oncogenic isoform of esr1 and methods of using the sameUNIV DUKE·Filed 2015·Application pending·0 cites
- 2144US2018282736A1Her3 vaccine vector compositions and methods of using the sameUNIV DUKE·Filed 2018·Application pending·0 cites
- 2241US2019070154A1New methods of use for an anti-diarrhea agentUNIV DUKE·Filed 2016·Application pending·0 cites
- 2331US2017015758A1Compositions And Methods For Modulating And Redirecting Immune ResponsesMEDIMMUNE LLC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Herbert K. Lyerly files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →